| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.21 | 0.008 |
| mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.008 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.12 | 0.008 |
| mRNA | AG-014699 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.009 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.19 | 0.009 |
| mRNA | BRD-K99006945 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.01 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | 0.1 | 0.01 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.01 |
| mRNA | BIBW2992 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.01 |
| mRNA | BMS-708163 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.01 |